- John Maslowski, currently Forge’s Chief Commercial Officer, will succeed Timothy J. Miller as CEO effective October 1, 2024.
- Under Dr. Miller’s leadership, Forge Biologics completed a $620 million acquisition by Ajinomoto Group and expanded its manufacturing capabilities.
Forge Biologics, a manufacturer of genetic medicines and part of the Ajinomoto Biopharma Services group, has announced a leadership change. Timothy J. Miller, Ph.D., will step down from his role as Chief Executive Officer after nearly five years. John Maslowski, the company’s current Chief Commercial Officer, has been appointed as the new CEO, effective October 1, 2024.
Maslowski brings over 25 years of experience in the biopharmaceutical industry to his new role. His previous positions include President and CEO of Castle Creek Biosciences, Inc., and Fibrocell Science, Inc. He joined Forge in June 2021 and has been instrumental in building the company’s commercial strategy, which supports nearly 50 clients. Maslowski’s experience includes advancing cell and gene therapies through pivotal clinical trials and regulatory approvals.
Dr. Miller, who co-founded Forge Biologics in 2020, oversaw significant growth and development of the company. His tenure included expanding the company’s 200,000 square foot manufacturing facility and leading Forge through a $620 million acquisition by Ajinomoto Group. “I am immensely proud of what we’ve accomplished at Forge,” Dr. Miller said. “Under John’s capable leadership, I am confident that Forge will continue to fulfill the bold mission that we set out to achieve.”
Overview of outsourcing trends 
